Koers BIOLASE Inc Nasdaq
Aandelen
US0909111082
Geavanceerde medische apparatuur & technologie
Omzet 2024 * | 50,67 mln. 46,67 mln. | Omzet 2025 * | 54,66 mln. 50,34 mln. | Marktkapitalisatie | 5,31 mln. 4,89 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -10 mln. -9,21 mln. | Nettowinst (verlies) 2025 * | -6 mln. -5,53 mln. | EV/omzet 2024 * | 0,1 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,1 x |
K/w-verhouding 2024 * |
-0,37
x | K/w-verhouding 2025 * |
-1,69
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,67% |
Recentste transcriptie over BIOLASE Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
John Beaver
CEO | Chief Executive Officer | 62 | 01-10-17 |
Director of Finance/CFO | 53 | 01-02-21 | |
Steven Sandor
COO | Chief Operating Officer | 44 | 01-04-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jonathan Lord
CHM | Chairman | 69 | 01-08-14 |
John Beaver
CEO | Chief Executive Officer | 62 | 01-10-17 |
Director/Board Member | 73 | 16-08-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+11,91% | 227 mld. | |
+15,46% | 197 mld. | |
+18,58% | 141 mld. | |
+30,36% | 110 mld. | |
+0,65% | 64,15 mld. | |
+17,74% | 53,72 mld. | |
+5,82% | 51,75 mld. | |
+11,23% | 45,2 mld. | |
+5,73% | 37,37 mld. |